Clinical Trial Update: Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MAXOMAT for growth in young children with Noonan syndrome has completed. The sponsor is Sanofi.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Noonan Syndrome

Drugs mentioned

• MAXOMAT

Snippet

Sponsor: Sanofi | Conditions: Noonan Syndrome | Phase 3 | Status: COMPLETED